GILD vs BIIB — Key Metrics
| Metric | GILD (GILEAD SCIENCES INC) | BIIB (BIOGEN INC) |
|---|---|---|
| Price | 149.05 | 225.88 |
| Market Cap | 184.82 Billion | 33.37 Billion |
| P/E (TTM) | -57.33 | 39.77 |
| P/B (Quarterly) | 13.717 | 1.64 |
| P/S (TTM) | 6.07 | 3.33 |
| Net Profit Margin (TTM) | -10.6 | 8.3 |
| Gross Margin (TTM) | 79.6 | 74.0 |
| ROE (TTM) | -16.3 | 4.5 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
GILD · GILEAD SCIENCES INC
Outperform
BIIB · BIOGEN INC
Outperform
Recommendation Summary
Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: GILD.
Financial Metrics
Prices delayed ~15 min
| GILD | Metrics | BIIB |
|---|---|---|
| $149.05 | Price | $225.88 |
| — | Market Capitalization | — |
| 6.07 | Price to Sales | 3.33 |
| 14.28 | Price to FCF Ratio | 12.48 |
| 7.62 | Price to Gross Profit | 4.5 |
| 30.47 | Price to R&D | 16.57 |
| 13.25 | Price to Current Assets | 4.57 |